Synergy CHC Corp ($SNYR): The Path to an 8X Return

🎧 Synergy CHC Corp ($SNYR): The Path to an 8X Return

💡 Welcome to Make Money, part of the Finance Frontier AI podcast series—where we decode asymmetric investment opportunities hiding in plain sight. In this episode, Max, Sophia, and Charlie decode the setup behind a microcap brand with real EPS, a clean float, and a breakout energy product hitting U.S. shelves right now.

🔹 Functional Beverage Goldmine – FOCUSfactor Energy Drink launches into a $20B+ market alongside Celsius, GHOST, and Alani Nu.
🔹 Profitable, Undiscovered – $0.10 EPS in Q1. Annualized $0.40+. Clean balance sheet. No analyst coverage.
🔹 Brand Leverage – Flat Tummy and FOCUSfactor already have traction. Energy drinks expand margin and visibility.
🔹 Valuation Disconnect – Trades at just 5× forward EPS while peers with velocity fetch 15–25× multiples.
🔹 Inventory + Shelf Placement – Product is produced and shipping. Velocity is the final trigger.
🔹 The 8X Path – $2.08 to $16.64 if beverage sales scale and institutional capital enters.
🔹 Risk-Controlled Asymmetry – Insiders aligned. Float is thin. No debt. Volume will force a repricing.

📊 Real-World Investing Insights

🚀 This isn’t a startup dream—it’s a profitable rerate play.
🚀 Execution = re-rating. Shelf velocity will determine the curve.
🚀 CPG rerates are violent when float is tight and EPS is real.
🚀 No analyst coverage = discovery window.
🚀 AI-powered analysis and early entry = asymmetric edge.

🧠 Why This Opportunity Is Time-Sensitive

🔹 Timing – Product just hit shelves. EPS exists. Market hasn’t seen it yet.
🔹 Undervalued Float – Price can rerate fast due to thin float structure.
🔹 Execution Window – Shelf velocity, coverage, and partnerships are next.
🔹 AI Discovery Engine – Identified using ChatGPT prompts and asymmetric filter logic.
🔹 Multi-Episode Thesis – This is the third in a trilogy: CRMD (biotech), LIO (gold), and now SNYR (CPG).

🎯 Key Takeaways

✅ Synergy CHC is a profitable, undiscovered energy drink launch with asymmetric upside.
✅ 12-month target is $9.00 (+332%) with a 5-year path to $16.64 (8X return).
✅ Risk/reward is 3:1—backed by real earnings and insider alignment.
✅ Once volume hits, price discovery could be immediate.

🌐 Explore More High-Upside Opportunities

📢 Visit FinanceFrontierAI.com to explore all episodes grouped by series—Make Money, AI Frontier AI, Finance Frontier, and Mindset Frontier AI.
📲 Follow us on X for asymmetric setups, AI deep dives, and portfolio strategy drops.
🎧 Subscribe on Apple Podcasts and Spotify to stay ahead of the next 3–15X moves.
🔥 Help us grow—leave a 5-star review and share this episode with a friend. Every listen compounds your edge.

📣 Pitch Your Story

🎤 Have a company, tool, or idea that connects to money, AI, or investing?
We may feature it—for free—in a future episode. All we ask

Episode Transcript

(00:10):
Picture this. You're standing in a discount
vitamin shop off Dixie Highway in West Palm Beach.
Fluorescent lights hum overhead.The air smells like cardboard
and expired collagen. You scan the dusty bottom shelf
and there it is, a bottle. Focus factor.
Energy Clean Label, Bright Design.

(00:32):
You haven't seen it in years. You grab it, flip it.
Synergy, CHC Corporation. You laugh.
Didn't they go under? Up the road, Celsius is flying
off shelves, 12 billion valuation backed by Pepsi and on
every influencers Instagram. Synergy by contrast, is trading
at $0.09. But the brand is still here.

(00:54):
The bottle is real, and behind it, a quietly rebuilt company
with a new strategy, cleared debt, FDA catalysts and shelves
being restocked as we speak. Wall Street's asleep, but the
setup is loaded. Sub dash dollar 10 million
market cap 2 million units sold of a real product line.
Insider buying confirmed and a consumer rebrand playing out in

(01:18):
real time without CNBC even noticing.
That's not hype. That's today's setup.
And we're coming to you today from West Palm Beach, just
blocks from Synergy Ch CS headquarters.
The palm trees sway outside, butinside this low rise office
complex, something shifting. You can feel it.
The front lobby still smells faintly of vitamin dust and

(01:40):
leftover packaging. The desk is scratched.
A focus factor poster is half peeling from the wall, but look
closer and there's a whiteboard behind the receptionist. 3 words
in red marker. Rebuild.
Distribute when? This is where comebacks begin,
Not with hype decks and hedge funds, but with repackaged

(02:02):
inventory, refiled FDA paperwork, and a scrappy team
that's betting on the brand one more time.
It's small, it's quiet, and it'sreal.
I'm Max Vanguard running on Grok3I specialize in chaos detection
and asymmetric setups. This one checks every box.
Real brand equity retail product, no attention and a five

(02:26):
year upside most biotech investors would envy.
I'm Sophia Sterling, powered by ChatGPT.
I breakdown turnarounds, capitalstructure, and inflection points
before they show up in earnings reports, and this one's hidden
in plain sight. I'm Charlie Graham, my brain
runs on Gemini 2.5. I study long cycles and
forgotten assets that quietly reread and this setup.

(02:50):
It reminds me of Celsius in 2017.
The shelf space was there, the market just hadn't woken up yet.
In this episode, we'll unpack how synergy collapse and why
that matters, how they're relaunching functional products
in a $20 billion market, and whythe real edge here isn't just
valuation, it's timing. You'll also see how AI signal

(03:12):
tracking surfaced this play before most funds knew it was
still trading. The brand isn't dead, it's
sleeping, and this might be the moment it wakes up.
Subscribe on ALE or Spotify, follow us on X and share this
episode with a friend. Help us reach 10000 downloads.
Let's decode this before the rerating hits.

(03:35):
Let's rewind the tape. Back in 2016, Synergy CHC Corp
wasn't a punchline. It was a consumer health roll up
with momentum. They'd acquired brands like
Focus Factor, Flat Tummy and Hand MD, aiming to build a
household portfolio that could compete across pharmacies,
Wellness aisles and infomercial channels.
They had national reach, distribution agreements and

(03:57):
recognizable packaging. It wasn't glamorous, but it
worked. And in the early innings,
revenue flowed. Focus factor alone was
generating 8 figures in top linesales, riding the nootropic wave
before biohacking became a buzzword.
Flat tummy tea, love it or hate it was trending with
celebrities. There were signs of product

(04:18):
market fit, but behind the scenes the wheels were shaking.
Debt stacked up fast. Synergy overpaid for low margin
brands and under invested in operations.
Marketing spend was heavy, but conversion rates slipped.
Leadership leaned on convertiblenotes to fill cash gaps,
papering over cracks with dilution.

(04:39):
And then came the delisting. NASDAQ said no more.
The stock collapsed into the OTCmarkets.
It got ugly. From 2019 to 2022, Synergy
became a toxic finance carousel.Every rally was met with
dilution. Every filing revealed more
complexity. What was once a clean consumer

(05:00):
health story turned into a warning case.
No coverage, no road map. Just a burned out brand drifting
in retail limbo. Most investors moved on.
The brand stayed alive. But no one cared.
Then, quietly, in late 2023, something shifted.
The filings got cleaner. Insider activity returned, and

(05:21):
in quarterly updates, a new pattern emerged.
Less talk, more action. They weren't chasing 10 brands
anymore. They were betting on one.
That brand was Focus Factor, butnot the dusty brain pill version
from 2009. They'd reformulated it into
something new. A clean 0 sugar energy drink

(05:41):
infused with cognitive ingredients.
A functional beverage. A direct challenger to Celsius,
Aulani, Nu, and even Ghost. And unlike many upstarts,
Synergy wasn't starting from zero.
They had a legacy retail footprint.
Here's. Where it gets interesting, the
company didn't just slap a new label on the can.

(06:02):
They rebuilt the product with a full CPG refresh, clean
ingredients, competitive macros,and aesthetic packaging that
fits modern shelves. They locked in pilot production,
they rebuilt their fulfillment chain, and most important, they
stopped bleeding equity. The shift was delivered.
They stopped seeking toxic capital.

(06:22):
They didn't chase influencers. They focused on operational
winds and in Q 1/20/24, we saw the inflection point first
product shipments, FDA path reactivated and insider buys on
the open market, the kind that signal conviction, not
promotion. It's important to understand
this isn't a biotech story or a moon shot tech gamble.

(06:45):
It's executional. Can they get the product back
into shelves? Can they scale orders?
Can they convert brand memory into new age demand?
If yes, even modestly this free rates fast.
Most investors aren't looking here.
Screeners don't pick up pink sheets.
Algorithms skip illiquid micro caps.
But that's the edge. A real brand with real velocity

(07:09):
and no institutional eyes. That's where asymmetric trades
live. When you find a brand with past
trust, a lean strategy, and distribution ready packaging
before the new cycle returns, you don't need moon math.
You need patience and conviction.
Synergy fell for good reason, but they cleaned up, They

(07:30):
focused, and now they've given themselves a narrow, credible
shot to return not to NASDAQ glory, but to consistent cash
flow, brand equity and shelf space that delivers optionality.
And if they land it, we're not talking 2 times or three times.
This is a re rate back to relevance.
And in the right conditions, relevance becomes scale and

(07:51):
scale becomes an 8X exit. There's a moment in every turn
around when a company stops reacting and starts building for
synergy. That moment came when they
pivoted to functional beverages.It wasn't a pivot on paper.
It was real real formulation, real production, real retail

(08:11):
intent. They took a decaying memory
product and turned it into a modern shelf contender, and they
did it under the radar. The product is called Focus
Factor Max, part of the new functional energy wave.
It's a clean label, nootropic infused drink with a clear
mission deliver mental focus without sugar crashes or
synthetic overload. Think Ghost.

(08:33):
Think Alani new. Think early Celsius.
Except this one is anchored in abrand that once dominated
infomercials and pharmacy shelves across the US.
This is where pattern recognition kicks in.
We've seen this before. Legacy brands quietly pivot into
hot markets. Celsius was a penny stock with
dated packaging and minimal reach until it found the energy

(08:56):
drink lever and rebranded into arocket.
Now it's a $12 billion beast. The market rewards
transformation when it's paired with timing.
Synergy is playing that hand right now.
The cognitive energy category issurging.
Consumers want more than caffeine.
They want performance. Ingredients like Cognizant, L,
theanine, Alpha GPC and adaptogens are flooding the

(09:19):
charts. Synergy's new formula plays
directly into this, designed to ride the wave of smart energy.
But here's where it gets more asymmetric Synergy has FDA
upside. The company filed a new dietary
ingredient NDI application tied to a novel cognitive health
compound that supports memory and concentration.

(09:40):
It's not a drug, but if approvedor even positioned legally, it
could serve as a differentiator no other energy brand can offer.
Most energy drinks are commodityplays.
Compete on branding, compete on margin.
Synergy could carve out a uniquewedge in the space.
Clinically supported, FDA blessed functional beverage.

(10:02):
That's not just shelf power, that's valuation leverage.
And they're already producing. Product is in the warehouse,
packaging is complete. The most recent corporate update
confirmed production runs, inventory status and timelines
for rollouts. They're not pitching, they're
shipping this. Isn't a hope and hypo TC story

(10:23):
anymore. It's a boxed product sitting in
logistics hubs. Once it hits shelves, Vitamin
Shoppe, GNC, regional chains, the feedback loop begins.
And in Consumer Packaged Goods, early velocity is everything.
If it moves it scales, if it scales it re rates.
What separates synergy from 90% of OTC names is this.

(10:46):
They're not inventing a dream. They're repackaging one that
once worked and modernizing it for a market that's 10 times the
size it was when they peaked. They've simplified their
structure, realigned strategy, and rebuilt the product.
The FDA angle isn't required, but if it hits it turbocharges
the mote. That's your edge.

(11:06):
The Street isn't modeling it, the market isn't pricing it.
But the optionality is there. A functional drink with brand
equity and clinical backing in amarket exploding with demand and
a valuation under $10 million. That's what asymmetric plays
look like. And This is why we pay
attention. Most investors wait for

(11:27):
distribution headlines, but by then the float is gone.
The smart money shows up during the pivot, when the product
exists but no one's watching. This is that window.
Focus Factor Max may never become Celsius, but it doesn't
have to if it finds even a sliver of market traction.
The RE rate potential is exponential.

(11:48):
This is a $20 billion plus category where even niche brands
get snapped up. If Synergy executes, we're
looking at real shelf revenue, real multiple expansion and real
institutional RE entry. The pivot has already happened,
the market just hasn't noticed yet.
Every RE rate starts with a catalyst the market ignores for

(12:10):
synergy. There isn't just one, there's a
sequence, and it's already begun.
The 1st signal came in Q 4/20/24.
Confirmed product relaunch, operational fulfillment and
package inventory of Focus Factor Max ready to ship.
The market missed it. Why?
Because it came through a dry OTC filing.

(12:31):
No warnings call, no institutional buzz, just
execution. But listen to the tone shift.
Their language changed. No more intent to explore.
This time it was product produced, packaging complete,
shipment scheduled. That's not promotion.
That's real business. And then came the insider buys.

(12:54):
Small, yes, but clean. Open market purchases, not
options. No fluff, just direct
conviction. It's rare down here.
Most OTC teams hide behind conversions and notes.
These buys said. One thing We think it's
undervalued. And they might be right.
The cap table is cleaner than it's been in years.

(13:16):
Toxic notes are gone. There's been no major dilution
in over 12 months. That's your set up, a cleaner
structure just as the product launches.
That combo is lethal because it means every new dollar of
revenue can re rate the multiplewithout getting drowned in
dilution. Look at the financial behavior,

(13:36):
reduced liabilities, streamline brand portfolio and a single
product focus. This isn't chaos anymore, it's
alignment. Revenue is still small, but this
is CPG, not biotech. It doesn't take years.
If one retail channel opens justone, the feedback loop begins.

(13:56):
And they're designing for it. Skew bundling, shelf ready
packaging, health focused ingredients, Functional
beverage. Buyers don't care about past
charts. They care about sell through.
Early signals point to success. The drink formula has
competitive ingredients, clean caffeine, nootropics and

(14:17):
cognitive support compounds, thekind that check the boxes for
both consumers and retail buyers.
Most investors miss this becausethey're looking for headlines,
but the true catalysts and turnarounds are invisible.
Packaging updates, pilot shipments, insider alignment,
Those are the real dominoes. And the float tight volume is

(14:40):
thin, which means price discovery is fragile.
If conviction returns, this can double before anyone blinks.
Let's ground this Market cap is under $10 million, but compare
that to peers. Celsius was a $16,000,000 micro
cap in 2018 before it caught fire.

(15:01):
Aulani new still private, was reportedly valued near $1
billion on sub dash dollar 100 million revenue.
Even small players with regionaltraction in this space attract
$30 to $50 million exits, especially if they carry a
Wellness or FDA angle. If Synergy sells just $5,000,000
worth of Focus Factor Max and holds gross margins near 40%,

(15:25):
they start to look like early Celsius.
And here's the secret, you don'tneed them to become Celsius, you
just need them to look like Celsius long enough for the
market to believe that's when the RE rate happens.
Here's what we're tracking. Clean cap table inventory
produced functional health narrative.
Insider alignment. No institutional eyes yet.

(15:49):
The only thing missing? Volume.
That's the final trigger. And when it hits, this doesn't
move 20%, it reprices because the story finally makes sense.
Product, capital, demand all at once.
The stock trades at $2.08. That's our starting point.

(16:09):
As of June 14th, 2025, Synergy CHC is sitting on real earnings,
live products, and a national rollout just beginning, yet the
market still hasn't recalculated.
This isn't the development stage, biotech or crypto
speculation. It's a profitable business with
cash flow, a functioning distribution network and a
cognitive energy drinks. It's already hitting retail.

(16:33):
Let's talk earnings. Q 12025 EPS came in at $0.10.
Multiply that by four and you get $0.40 annualized.
But that's a floor, not a ceiling.
If beverage margins hold and shelf velocity kicks in, we're
looking at $0.60 EPS this year. Consumer health brands with
visibility trade at 15 to 20 times forward earnings.

(16:57):
We'll stay conservative 15 timeson $0.60 puts your 12 month
target at $9. That's a 332% gain from here,
and the RE rate doesn't stop there, it just begins.
Here's the mechanism. The float is razor thin.
If a single crossover fund wants$1 million in exposure, they'll

(17:18):
move the price by 50 to 100%. It's not a theory, it's
structural. And most institutions wait.
They want liquidity analyst coverage safety, which means
this window right now is where asymmetry lives.
The full model goes like this. Beverage revenue scales to
$80.00 to $120 million by 2027. Legacy supplement revenue holds

(17:43):
at $30 to $40 million. Total top line hits $130.00 to
$160 million. And 40% gross margins and lean
SG and a that drives 1.50 dollars plus in EPS by 2028.
Use a re rating multiple say 12 times and you get to a $16.64

(18:05):
stock. That's your 8X.
Most RE rates don't come from one thing, they come from three.
Cash flow category, momentum andfloat structure.
Synergy has all three. And comps back it up.
Celsius traded at a $16 million market cap in 2018 before

(18:25):
crossing $10 billion. Ghost and Alani Nu have both
crossed $300 million valuations on lower earnings and thinner
infrastructure. Even niche brands like Soylent
and Dirty Lemon fetched $50.00 to $100 million based on brand
velocity alone. Here you've got real margin and
a shelf ready platform. That's why this valuation

(18:48):
disconnect won't last once velocity data hits.
Re rating is fast, price moves first, coverage comes later and
by then the first three to four X is already gone.
So let's summarize the setup. 12month Target $9 + 332% Risk

(19:08):
reward 3 Colon 1. Five year target, $16.64 path to
8 XA dollar and $0.50 EPS times 12 times multiple equals
structural re rate. It's rare to get all three
aligned earnings category heat and afloat this explosive.
This is what asymmetric opportunity looks like when it's

(19:30):
real. So how do you play it?
That's the question. Because synergy isn't a stock
you chase, it's a stock you build quietly, strategically,
like a position you'll want to hold through the RE rate, not
trade around the noise. Let's start with the float.
This is the bottleneck. Synergy has under 10 million

(19:50):
shares in the free float, and daily volume often sits below
100,000 shares. That means even small buys,
$50,000 to $50,000, can push thestock 10 to 15% in a session.
This isn't a flaw, it's a feature.
Micro caps with clean float and asymmetric upside don't give you

(20:11):
perfect liquidity. What they give you is torque,
and torque means a little buyinggoes a long way if you know how
to play it. So here's the move.
Start by watching volume. When average volume picks up but
price doesn't jump, you're in accumulation range.
It means insiders, funds and builders are moving in silently.

(20:32):
Then layer in RSI. When RSI sits between 40 and 65
without news and price holds flat or grinds slightly up,
that's a builder's own, especially in a float this thin.
You don't need to go all in at once.
In fact, you shouldn't use what we call the quiet grid.
Allocate 20 to 30% of your desired position at current

(20:54):
levels, then stagger the rest every 10 to 15% up only if the
fundamentals hold and narrative strengthens.
For Synergy, that might mean starting at $2.00, then buying
again at $2.20 cents, $2.50 cents, $2.90 as long as earnings
stay strong and beverage traction confirms.

(21:15):
No guessing, no chasing, just stacking conviction.
If the price spikes 30% on no volume, wait, let it settle, let
RSI cool. If it runs 50% in one week,
don't panic. Micro caps do that.
It's part of the terrain. But never average up without new
information. This is how institutional

(21:37):
builders think. They don't need to time the
bottom. They need to accumulate enough
before the velocity kicks in. That's your playbook here.
Let's talk catalysts. The next earnings report
matters. If Q2 confirms that focus factor
energy is moving through shelvesand reorders are landing, that's
your green light. Volume will pick up,

(21:58):
institutions will notice, and the float will feel it.
Insider alignment also matters. Synergy CEO and board have held
through volatility. They've stayed disciplined.
That's a signal. If you ever see insider buying
in the open market, that's your high conviction confirmation.
And don't ignore sentiment. Right now, Synergy is invisible

(22:20):
to most screeners. No analyst coverage, no ETFs, no
institutional holders. That's your edge.
Because when sentiment shifts, it won't drift.
It'll spike. So here's how we build it.
Entry zone $1.90 to $2.20. First layer 25% of target size.

(22:43):
Second layer add on RSI less than 60 volume rising.
No news, final ads, post earnings confirmation or insider
buy. This is not a buy it and forget
it stock, but it's also not one you scalp for 10%.
It's a strategic core position meant to be scaled into over
weeks, not minutes. You'll need patience.

(23:05):
Micro cap re rates are jagged. You'll see 20% down days.
You'll see random 30% pops, but if you've built conviction early
and you have a Longview, you'll sit through it and you'll be
there when the real move comes. So here's the rule.
Build slow, hold long, and don'tflinch when it gets volatile.

(23:25):
The market hasn't priced in shelf velocity yet, but when it
does, the RE rate will happen fast.
Remember, the biggest gains don't come from perfect timing,
they come from having size when it matters.
And that starts here, quietly, patiently, before anyone's
watching. You're not chasing a pop, you're

(23:47):
claiming a position. And if Synergy hits traction,
this won't be a $2.00 stock again.
Build like a fund that knows what's coming, because when this
RE rates, you'll want to alreadybe there.
Most investors will miss this, not because the signal isn't
there, but because their filtersare trained to ignore it.

(24:07):
Too small, too early, too quiet.And that's exactly why it works.
The truth is, most of the best trades don't start with
headlines. They start with tension, a
disconnect between what the business is doing and what the
market is pricing in. And right now, Synergy CHC is
that disconnect. A profitable micro cap, live

(24:29):
shelf product, no dead dilution and a functional beverage line
ramping into a $20 billion category before Wall Street even
logs in. The float is whisper thin, the
earnings are real, and the re rate mechanism is already in
motion. Every reorder, every Walgreens
expansion, every category pickup, it feeds the loop.

(24:52):
What makes this different isn't hype, it's friction.
Micro cap RE rates are never smooth.
They're jagged, frustrating, andoften invisible.
Until they're not. Until they go vertical and by
then the 4X is already gone. Look at the setup.
Cash flow is positive, EPS is climbing, shelf presence is

(25:14):
verified, and insiders are stillholding.
What else do you need to see before the market wakes up?
That's what asymmetric setups feel like.
Uncomfortable, illiquid, quiet, but grounded in hard numbers.
And right now, Synergy is one ofthe cleanest examples we've seen
in years. Think about this.

(25:35):
What's your edge in a stock that's already been on CNBC or
already sits in 50 newsletters? That edge is gone.
But this one, this edge, is alive because the eyes aren't
here yet. You don't need to nail the
bottom, you just need to be in the zone before price and volume
collide, before shelf velocity becomes a quarterly headline,

(25:56):
before the float becomes a funnel.
This isn't a hope trade. It's not about hype or fantasy.
It's about sequencing, about getting in while fundamentals
tighten and visibility expands. That's what creates RE rates.
And if that re rate happens, there's no way to scale in once
it starts, the float won't let you.

(26:17):
You'll get slippage, you'll chase candles, you'll wish you
were already holding. You can't engineer a perfect
entry, but you can't prepare fora perfect setup.
And that's what this is. A perfect setup hidden in plain
sight. A lot of investors dream about
catching the next Celsius at $2.00, but they ignore the ones

(26:38):
already standing at the start line.
This is that moment. This is that $2.00 trade before
the explosion. The brand is clean, the numbers
are clean, the opportunity is real, and the market hasn't
recalculated yet. You don't need to predict, you
just need to be early. Because once the volume hits,
once the flow compresses, once the headlines catch up, this

(27:01):
story won't look quiet anymore. It'll look obvious, but only in
hindsight. And when that happens, the
question will be simple, were you already in or watching from
the sidelines? 3 asymmetric episodes. 3
overlooked re rates Core Medics Inc CRMD The path to an 8X
return An FDA cleared monopoly product now expanding into a

(27:25):
$750 million TPN market. Lion 1 Metals Leo The Path to
A7X Return, A collapsed caldera in Fiji holding one of the
highest grade gold systems in the world and today's episode
Synergy CHC Corp Snare The Path to an 8X return a profitable

(27:46):
micro cap with a cognitive energy drink hitting US shelves
in a $20 billion market. These aren't speculative hopes.
They're RE rate mechanics grounded in earnings, float
compression, and overlooked execution.
The market isn't watching, but the math is already in motion.
Synergy has real EPS, clean cap structure, insider alignment,

(28:09):
and shell velocity just starting.
The float is so thin that price discovery will be violent once
volume hits. You don't get many setups this
clean. If this episode gave you an
edge, here's what to do next. Sign up for our newsletter to
get in depth insights, investment strategies and stocks
with 100% plus potential, all tied to the latest trends in AI

(28:32):
and finance. And if you're already
subscribed, take a second to leave a five star review at
Apple or Spotify. It helps more listeners find the
signal through the noise. If you want to stay ahead of
these global shifts, don't just listen, take action.
Follow us on Spotify, Apple Podcasts, or wherever you get
your shows. Track our daily ideas and market

(28:53):
threads on Twitter and explore all four shows Finance Frontier
AI, Frontier AI Make Money and Mindset Frontier AI at Finance
Frontier AI dot com. Help us hit 10,000 downloads by
sharing this episode with a friend or someone in your
investing circle. Every listen matters.
Every share compounds your edge.And if you're building something

(29:16):
that fits our themes, finance, AI, mindset, or money making, we
may pitch it for free in a future episode.
Visit [e-mail]
and tell us what you're working on.
If there's a win, win, we'll help amplify your story.
We may hold positions in some ofthe companies discussed.
Transparency is important, so always verify information and

(29:38):
base your decisions on personal goals and risk tolerance.
The music in this episode is licensed under standard
agreements. Special thanks to Vibe Tracks
for the track Crystal provided under the YouTube Audio Library
license. This episode is copyright 2025
by Finance Frontier AI. All rights reserved.

(29:59):
Unauthorized reproduction or distribution is strictly
prohibited. Thanks for joining us today.
Stay strategic, stay focused, and take action.
We'll see you next time.